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Treatment of human polymorphonuclear leukocytes 
(PMN) with anthralin (0.2-50 J.Lg/ml) results in dose-
dependent inhibition of nondirected as well as directed 
migration (chemotaxis) against the synthetic tripeptide 
N-formy 1-methiony 1-leucyl-phenylalanine (FMLP), the 
complement fragment C5a and leukotriene B 4 • Polymor-
phonuclear leukocytes (PMN) pretreated with anthralin 
at concentrations which inhibit cell motility also show a 
dose-dependent inhibition of superoxide anion genera-
tion. In contrast to anthralin two derivatives (danthrone 
and anthralin dimer) were ineffective. 
Specific binding of [3 H]FMLP to neutrophil membrane 
receptors was impaired by anthralin at concentrations 
5-10 fold higher than those which were inhibitory for 
cell function. Release of ,8-glucuronidase from azuro-
philic (lysosomal) granules provoked by various chemo-
taxins in the presence of cytochalasin B was not affected 
by anthralin over a wide range of concentrations. Also 
there were no signs of cytotoxicity e.g., leakage of cy-
toplasmatic lactate dehydrogenase (LDH) caused by an-
thralin. 
These data indicate that neutrophil functions may be-
come substantially altered by anthralin. The effective 
dosages correspond to concentrations obtained in vivo 
after local application. Danthrone as well as anthralin 
dimer, known to be clinically ineffective, showed no 
effects upon PMN function. It is suggested that anthralin 
via a free radical mechanism alters sensitive sites at or 
in the cellular membrane including receptors. 
Anthralin was introduced in 1916 by Galewsky [1] and Unna 
[2] and since then t his compound is widely used as an anti-
psoriatic remedy. Despite a great number of clinical and exper-
imental data the way anthralin affects clearing of psoriatic 
lesions is still not fully understood. Various investigators have 
shown that anthralin inhibits glycolytic enzymes in vitro [3-6] 
possibly by lipid peroxidation [7] . In recent years several studies 
pointed toward effects of anthralin on cell proliferation 
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[8- 11] . By its toxicity, anthralin provokes erythema and in-
flammatory changes in the upper dermis which are found to be 
unresponsive towards common anti-inflammatory agents 
[12, 13]. In addition, some of the effects seen in skin or in cells 
cultured in vitro are supposed to be based upon a free radical 
mechanism [14,15]. 
Clinical use of anthralin is mainly restricted to the treatment 
of psoriasis. In fact attempts to successfully apply anthralin to 
inflammatory skin conditions other than psoriasis have mostly 
failed. Because of this narrow therapeutic spectrum it appears 
reasonable to suppose that the way anthralin works may be 
related to specific features of psoriatic skin. 
In the present study we have investigated the effects of 
anthralin and two derivatives, danthrone and anthralin dimer, 
on human polymorphonuclear leukocytes (PMN) . These cells 
are known to play a role in psoriasis [16,18]. Our results show 
that in contrast to danthrone and the dimer, anthralin inhibits 
cell functions in PMN which are related to membrane activa-
tion. 
MATERIALS AND METHODS 
Chemicals 
Anthralin (Dithranol, 1,8-dihydroxy-anthrone) was a gift from Bayer 
AG, Leverkusen, F.R.G., and was free of impurities as assessed by thin 
layer c hromatography. It was dissolved in acetone (10 mg/ml) a nd 
diluted in phosphate-buffered saline (PBS) (Sigma Chemical Co., Mu-
nich, F.R.G.) containing 0.1 % bovine serum albumin (BSA) (Sigma) 
just before experiments were performed. 
Danthrone (1,8-dihydroxy anthraquinone) was purchased from 
Sigma Chemical Co. and dissolved as described for anthralin. Dimeric 
anthralin (1,8,1 '8' -tetrahydroxydianthrone) was synthesized according 
to the method of Auterhoff and Scherff [19]. Final purificat ion was 
assessed by preparative thin layer chromatography. Identity and purity 
has been proved by melting point, lR- and [1H]NMR spectra. Dimeric 
anthralin has been dissolved in acetone (10 mg/ml) and diluted as 
described for anthralin. 
The formylated tripeptide N-formyl-L-methionyl-L-leucyl-L-phen-
ylalanine (FMLP), ferricytochrome c (type III), phenolphthalein-{:1-o-
glucuronide, 4{:1-phorbol- 12-myristate-13-acetate (PMA), cytochalasin 
B, and superoxide dismutase (SOD) from bovine blood were purchased 
from Sigma. Platelet-activating factor-C,s-(PAF) was from Serva 
Chemie, Heidelberg, F.R.G. 
Leukotriene B. (L TB.) (a gift from Dr. Rokach, Merck, Frost Co., 
Toronto, Canada) was dissolved in methanol (stock solution, 0.1 mg/ 
ml). A pool (10 ng/ml) was obtained after dilution with PBS/BSA and 
stored below -70'C. C5 complement split product (C5a) was prepared 
in a sem i-purified form according to the method described by Fernandez 
and Hugli [20] and was used at concentrations optimal for chemotaxis, 
02 -release and enzyme release, respectively. 
Cell Preparation 
Human neutrophils were prepared from healthy persons as described 
earlier [16]. 
The final cell preparation used in all experiments contained more 
than 90% neutrophils with a viability of greater than 97% as assessed 
by trypan blue exclusion. 
Boyden Chamber Chemotaxis 
Blind well Boyden chambers (Bio Rad Laboratories, Munich, F .R.G.) 
were filled with the appropriate stimulus in PBS containing 0.1 % BSA. 
A cellulose nitrate filter (Sartorius, Giittingen, F.R.G., pore size 5 11m) 
covered the chemoattractant containing compartment and to the upper 
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compartment 50 Ill neutrophils (4 X 106/ml) and 50 JLl of various 
dilu tions of anthra-derivatives were added. 
Thereafte r the cells were incubated for 2 h at 37' C in a humirufied 
atmosphere conta ining 5% C02 and then t he fi lters were fix:ed, stained, 
and mounted on glass slides. Cells which had migrated to the lower 
filter side were counted under a microscope at 5 randomly selected 
high-power fields and expressed as cells/high-power field (HPF) . Cells 
which had fallen down from t he fi lter into the lower part of t he Boyden 
chamber were determined by measuring lactate dehydrogenase (LDH) 
activity by Triton X-100 lysed cells in t he lower part of t he Boyden 
chamber. This is described as t he endogenous component c hemotactic 
assay ("ECCA")-method [21]. In other experiments t he leading front 
method according to Zigmond an d Hirsch [22 ] was used. I n this case 
incubation t ime of Boyden chambers was 1 h. 
Chemotaxis Under Agarose 
Chemotaxis under agarose was carried out in a slight modification 
of the method described by Chenoweth and associates [23 ]. 
Briefly agarose was dissolved in hi -distilled water. After cooling to 
50' C, ten -fold concentrated medium TC 199, (Seromed, Mun ich) 
HEPES-buffer (1 M, pH 7.5) and gelatin (0.1 % final concentration) 
were added to give an isotonic solution, pH 7.3. 
This warm solu t ion was poured into Petri dishes, allowed to harden 
at 4 ·c and t hen side by side 3 wells were punched into t he agarose. 
The middle one contained 10 pl PMNs (5 X 107 ) with t he anthra-
derivative or buffer. T he outer wells contained t he stimulus and buffer, 
respectively. 
After 2 h incubation at 3TC in a humidified atmosphere containing 
5% C02, the cells were fi xed with 80% methanol and 8% forma ldehyde 
overnigh t and stai ned wi t h hematoxylin . The distance, which cells had 
migrated against t he stimulus minus t he distance, which cells had 
migrated random ly was taken as chemotactic migration (chemotactic 
differen t ial). 
In some cases, the cells moved without stimulation (random motil -
ity). In this case the random migra t ion distance is given. 
Superoxide (02) production 
Superoxide anion production was measured using a modification of 
the method described by English, Roloff, and Lukens [24]. Cells were 
incubated for 15 min at 37' C with appropriate dilut ions of t he anthra-
derivatives. Thereafter the cells were centrifuged, washed 2 times with 
PBS/BSA counted, and adjusted to 2 X 106/m l when FMLP was used 
and 5 x 105/ ml when PMA was used as stimulus. 
For C5a- and PAF-stimulation PMN were adjusted to 8 x 106/ ml 
and preincubated with cytochalasin B (5 JLg/ ml) for 5 min . 
Thereafter vials were cooled in an ice bath, centrifuged and super· 
natants were assayed for reduced cytochrome c by measuring extinc· 
tions at 550 nm and at 540 nm (Hitachi 100-80) . In other experiments 
SOD (10 Jlg/ ml) was added at the start of reactions to ev&luate SOD 
inhibi table cytochrome c reduction . 0 2 concentrations were calculated 
using an ext inction coefficient of 15.5 mM.cm (ferrocytochrollle c minus 
ferr icytochrome c) and expressed in nmoles reduced cytoch:rome c. 
Enzyme Release 
The marker enzyme for azurophilic granules, /3-glucuronidase, was 
measured as desc ribed previously [16] . 
PMN were preincubated wi t h t he anthra-derivat ive for 10 min at 
37 ' C. Thereafter cytochalas in B (5 Jlg/ml) was added and incubated 
with t he appropriate stimulus for 45 min at 37' C. After centrifugation 
(1000 g/10 min) t he supernata nt was assayed for /3-glucuronidase using 
phenolpht halein -/3-D-glucuronide as substrate. A 100% cont:rol for both 
enzymes was obtained by addition of 0.2% Triton X-100. Release of 
enzymes was expressed in percent of the 100% Tri ton X-100 control. 
In order to exclude cytotox ic effects the release of LDH after incu-
bation of PMN wi t h anthra-derivatives was determined. At concentra-
t ions up to 50 Jlg of ant hralin or dan t hrone per ml t he rele&se of LDH 
was 5.0 ± 3.2% (anthralin ) and 4.8 ± 2.9% (danthrone), whi le t he 
buffer control was 4.3 ± 2.7%. Sim ilarly, dimeric ant hra lin at concen-
trations up to 5 pg/ml caused no significant enzyme release (5.2 ± 
2.6%). However, with higher concentrations of t he dimer a significant 
release of LDH was noted indicating cytotox ic effects. 
Binding off H) FM LP to N eutrophiL5 
5 x 106 PMN in 100 Ill PBS (wit hout Ca++ and Mg++) conta ining 
0.1% BSA were incubated for 10 min with 100 JLl anthra li n at appro-
priate dilution s in PBS co ntaining 0.1 % BSA at 37' C. Then cell 
suspensions were cooled to o·c, mixed with 50 pi [3H]FMLl> (2 x 10-s 
M) in PBS and incubated for 10 min at O'C to minimize internalization 
of t he labeled peptide [25] . Thereafter 50 JLl ice cold PBS or for 
determination of nonspecific binrung 50 JLl unlabeled FMLP (2 x 10- 5 
M) were added and additionally incubated for 10 min at o·c. 
Peptide binrung on neutrophils was measured using a silicone oil 
centrifugation assay as described by Mackin et a! [25]. The method 
was morufied by using phthalic-acid-ru-n-butylester (Merck, Darm· 
stadt, F .R.G.) containing paraffin oil (DAB 8) (25:1, v/ v, PP) instead 
of silicone oil. 
A mixture of PMN, anthralin (or PBS) and FMLP was layered onto 
PP in plastic vials and centrifuged at 2000 gat 4' C. PP oil and free 
peptide were then removed by aspiration and the cell pellet was placed 
into a scintillation vial containing a t issue solubilizer (New England 
Nuclear). Following overnight incubation scintillation fluid (Packard) 
was added and the radioactivity was determined. Binrung of raruola-
beled FMLP was expressed in % control from 4 experiments using 
dupl icate determinations. 
RESULTS 
Random Migration and Chemotaxis 
Using blind well Boyden chambers anthralin is found to 
inhibi t chemotactic migration of human PMN in a dose-de-
pendent manner (Fig 1) . This impairment of cellular motility 
by anthralin is present within a n a rrow dose range (0.5- 10 1'-g/ 
ml, Fig 1) showing a 50 % inhibit ion dose (IDso) of 0.5 1'-g/ml 
with C5a as stimulus. Similar to C5a, dose-dependent inhibit ion 
by a n t hra lin was present when FMLP (IDso:0.5 !1-g/ml) or L TB4 
(ID50:0.6 !1-g/ml) were used at their optimal chemotactic concen-
t rations. 
Since anthral in in t he Boyden chamber system could influ -
ence P MN chemotactic activity by causing changes in cellula r 
adheren ce we have counted t h e number of cells adher in g t o 
t h e lower 's ide of the fi lter. Also PMN p resent in the lower 
chamber were counted. As a result there was no s ignifican t 
increase in the number of cells which had fallen down into the 
lower compartment under the influen ce of anthralin. 
Dan throne did not sh ow any inhibitory effects at concentra-
tions up to 20 !1-g/ml. Also, no effects were seen with dimeric 
a nthralin at con centrations up to 2 !1-g/ml (data not shown). 
Since the dimer is nea rly insoluble in buffer the amount of 
acetone needed t o solubilize dimeric a nthralin caused interfer-
en ce with migratory inhibition. In fact acetone at concen t ra-
tions above 10 !'-1/ml was able to inhibit chemotactic migration. 
Since this dose was needed to solubilize 10 1'-g anthralin dimer 
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FIG 1. Effects of anthralin upon C5a-induced PMN chemotaxis 
using Boyden chambers. Migrating cells per high power fie ld were 
counted and expressed as percent of PBS contro ls (ordinate ). Mean (± 
SO) of 4 series with t riplicate experiments are shown. 
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it appea rs likely that the inhibition seen at higher concentra-
tions of the dimer is due to acetone or the result of spontaneous 
crystallizat ion. 
ln contrast to chemotaxis, influences of agents which affect 
nondirected cellular motility are difficult to test in the Boyden 
chamber system. Therefore motility of PMN was determined 
using the "under agarose" method and compared with chemo-
tactic responsiveness. 
Fig 2 shows that nonstimulated (random) motility was inhib-
ited by anthrali n showing an ID50 near 10 11g/ml. This is similar 
to the dose causing inhibition of FMLP-induced chemotactic 
migration (Table I). Danthrone as well as anthralin dimer again 
proved to be without sign ificant inhibitory effects (Table I) . 
Under these experimental conditions no inhibitory effects were 
seen with acetone alone up to 2% (v/v). 
In addition, chemotactic migration was similarly inhibited 
by anthralin, when the leading front evaluation was used re-
sulting an ID50 of 0.7 ng/ml. This is close to the value obtained 
by the filter counting method (Fig 1). 
Oi Production 
Initial experiments revealed that ferricytochrome c becomes 
reduced nonenzymatically by anthralin (data not shown) . 
Therefore experimental conditions were chosen in which inter-
ference with the 0 2 assay becomes minimized. 
Neutrophils, after incubation with anthra-derivatives, were 
washed 2x with PBS and then stimulated with the appropriate 
stimulus. PBS was used as control. Table II demonstrates a 
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FIG 2. Effects of anthralin on PMN random moti li ty using the 
"under agarose" assay. Migration differences are expressed as percent 
of using PBS control (ordinate). Mean (± SD) of four series with 
quadruplicate experiments are shown. 
TABLE I. Effects of anthralin, danthrone, and anthralin dimer on 
chemotactic migration under agarose induced by FMLP" 
Concentration Chemotaxis(% of control•) 
(JJg/ml or JJI / ml) Anthralin Danthrone Anthralin dimer 
0 100 ± 4 100 ± 6 100 ± 4 
1 96 ± 4 100 ± 6 100 ± 5 
2 89 ± 4 104 ± 6 94 ± 5 
10 60 ± 3 98 ± 6 86 ± 4 
20 36 ± 5 98 ± 5 
100 0 92 ± 5 
" Mean (±SO) of 4 series of triplicate experiments. 
b Anthralin derivative-free buffer control. 
Acetone 
100 ± 4 
102 ± 6 
98 ± 5 
96 ± 5 
94 ± 4 
96 ± 4 
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TABLE II. Effect of anthralin, danthrone, and dimeric anthralin upon 
cytochrome c reduction by human PMN stimulated with C5a" 
Cytochrome c reduction (% of control•) 
Concentration 
(JJg/ml) Anthralin Anth ralin ' Dan throne 
0 100 100 100 
0.1 95 ± 5 87 ± 8 96 ± 7 
0.5 77 ± 6 84 ± 11 102 ± 10 
1.0 54± 9 94 ± 9 98 ± 8 
5.0 39 ± 9 130 ± 10 97 ± 7 
10.0 38 ± 7 134 ± 8 92 ± 4 
50.0 50± 9 236 ± 11 99 ± 7 
"Mean (± SD) of 4 series with duplicate experiments. 
b Anthea derivative-free control. 
'PMN not stimulated with C5a (buffer control). 
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FIG 3. SOD-inhibitable cytochrome c reduction of C5a (e) and 
FMLP (.6) stimu lated PMN under the influence of anthralin. Each 
point represents the mean of 4 series of duplicate experiments. For 
each experiment SOD-inhibitable cytochrome c reduction by nonstim -
ulated neutrophi ls was subtracted from SOD-inhibitable cytochrome c 
reduction by stimu lated neutrophils after anthralin treatment. The 
differences are expressed in percent of untreated control cells. 
decrease of cytochrome c reduction in cells which were prein-
cubated with anthralin at concentrations higher than 0.5 11g/ 
mi. On the other hand at concentrations above 10 11g/ml in-
creased cytochrome c reduction of PMN stimulated with C5a 
was noted. 
When PMN were incubated with anthralin without subse-
quent stimulation by C5a the cells also showed a significant 
increase of the reduction of cytochrome c above 5 11g/ml (Table 
II). This however could not be inhibited by SOD. In additioQ 
chloroform extracts of PMN pretreated with anthralin (1 11gj 
ml) contained anthralin as revealed by thin layer chromatog-
raphy (data not shown). This indicates that anthralin is indeed. 
responsible for the spontaneous cytochrome c reduction of 
anthralin treated cells. When this is taken into account, the 
SOD inhibitable cytochrome c reduction of PMN treated with 
dithranol gives a sigmoidal inhibition curve with an ID5o of l 
11gjml for C5a (Fig 3). Similar results were obtained with othet-
stimuli such as FMLP, PAF, and PMA (Table III). In contrast 
to anthralin neither danthrone nor dimeric anthralin inhibit 
the generation of 02 (Table II) . 
Release of (3-glucuronidase 
Degranulation with the release of lysosomal enzymes was the 
third parameter for PMN function which we examined in thi~ 
study. (3-Glucuronidase served as a marker signaling degranu, 
lation of azurophilic granules after stimulation with C5a as well 
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as FMLP in the presence o f cytochalasin with C5a as well as 
FMLP in the presence of cytochalasin B. 
Interestingly the release of fl-glucuronidase appeared not to 
be affected by any of the 3 compounds under study (anthralin, 
danthrone and the anthralin dimer) (Table IV). At concentra-
tions above 10 J.Lg/m l (Table IV) some inhibition of enzyme 
re lease was seen with t he anthra-compounds as well as with 
acetone. Therefore it appears likely that acetone again is caus-
ing the inhibition seen at higher concentrations. 
In experiments not shown it was determined that at maximal 
inhibitory doses of anthralin cytotoxicity as evidenced by the 
release of t he cytoplasmic enzyme lactate dehydrogenase was 
absent. In addition, care was taken to exclude interference of 
anthralin with the assays employed to measu re PMN functional 
parameters or, as indicated, controls were performed to measure 
the effects of solvents. 
Effect of Anthralin on [lH]FMLP Binding to Neutrophils 
Since in th is study inh ibition of receptor-dependent cell 
functions such as chemotactic migration and 0 2 release were 
inhibited it is possible that anthralin affects receptor binding 
at the cellu lar membrane. Therefore receptor-mediated binding 
of [3H ]FMLP to neut rophil s was examined. As shown in Fig 4, 
specific binding of [3H)FMLP to human neutrophils was mark-
edly a ltered by pretreatment of the ce ll s with anthralin concen-
trations higher than 5 J.Lg/ml. In addition [3 H]FMLP bound to 
neutrophils at OOC could be displaced by more than 70% by 
subsequent incubation of the cells with an excess of unlabeled 
FMLP. 
DISCUSSION 
We have studied functional parameters in human PMN 
under the influence of anthralin and two derivatives, dan throne 
and anthra lin dimer. 
Human PMN were used as target cells for two reasons: first 
in vitro binding of chemotactic factors to specific receptors on 
the cell membrane provokes multifunctional responses includ-
ing directional locomotion (chemotaxis), generation of super-
oxide an ions (02) and degrt~nulation (i.e., release of lysosomal 
enzymes, for review see [26]). In addition, while in a nonacti-
vated state, PMN show spontaneous nondirected migration. 
Thus neutrophil s appear to represent a sui table model for t he 
study of various cellular activit ies, some of which depend upon 
membrane function (e.g., production of 0 2 [27]) while in others 
(e.g., degranulation) addit ional events occur within the cell. 
TABLE HI. Fifty percent inhibitory dose (!Dr,o} of anthralin upon 
generation of 0 2- by human PMN stimulated with various chemotaxins 
Concentrations of 
chemotactic facto rs 
C5a (100 ng/ml) 
FMLP (10- 7 M) 
PAF (10 pg/ ml) 
PMA (10 ng/m l) 
ID.., 
anth ralin 
llg/ml 
1.0 
1.5 
0.8 
2.3 
Secondly, migration of neutrophils into the affected epider-
mis is a constant feature in psoriasis [28]. PMN are attracted 
by chemotactic factors not yet precisely defined and this could 
relate to the persistence of psoriatic tissue changes [29). 
Our results demonstrate that in the Boyden chamber system 
anthralin in contrast to dan throne and anthralin dimer inhibits 
locomotory activity of human PMN. At a dose range of 0.1- 10 
J.Lg/ml anthralin markedly affects PMN motility as well as the 
production of the superoxide anion (02). 
As compared to the Boyden chamber measurements the ID50 
of anthralin in the "under agarose" method was nearly 20-fold 
higher. This difference could be explained by the fact t hat in 
the "under agarose" assay the cell density was nearly 20-fold. 
In addit ion , diffusion of anthralin into agarose could similarly 
cause increases in the ID50 seen in the "under agarose" assay. 
Migration of PMN involves a complex series of events in-
cluding changes in membrane fluidity [30), alteration of the 
transmembrane potentials [31,32), and reversible adhesion and 
spreading [33), a ll of which could be affected by the drug. 
Furthermore, the generation of 02 is known to depend upon 
reactions mediated by NAD(P)H oxidase, flavin , and cyto-
chrome b, all of which are located within the plasmalemma 
[34]. Since there is a profound inhibition of 02 production 
which is similar to the inhibition seen in cellular motility our 
results make it likely that anthralin alters functio nal sites of 
the PMN membrane. Among these receptor binding of tritiated 
FMLP appears to be less sensitive to the action of anthralin as 
compared to motility and 02 production. 
Mustakallio [35] recently pointed out that the plasma mem-
% 
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Frc 4. [3H]FMLP binding of human neutrophils under t he influence 
of anthralin. Specific (displaceable) binding (e) is shown. Control data 
for buffer '( C) as well for acetone (A) 5% (v/ v) are included. 
TABLE IV. Effects of anthralin, danthrone, and dimeric anthralin on (3-glu.curonidase liberation. of chemotaxin stimulated neu.trophils" 
11-glucuronidase liberation( % of control•) 
Concentration Anthralin 
(!lg or 1'1/ ml) C5a FMLP 
0 100 100 
0.5 103 ± 10 97 ± 7 
1 103 ± 10 93 ± 7 
5 100 ± 7 87 ± 10 
10 94 ± 9 87 ± 5 
50 74 ± 10 63 ± 10 
"Mean (±SD) of 4 series witil dup licate experi ments. 
• Anthra derivative-free control. 
Dan th rone 
C5a FMLP 
100 100 
116±9 112±8 
120 ± 7 112 ± 11 
120 ± 8 110 ± 11 
116±6 98 ± 7 
118±9 99 ± 9 
Dimeric anthralin Acetone 
C5a FMLP FMLP 
100 100 100 
115 ± 11 111 ± 10 
113±8 104 ± 9 98 ± 2 
114 ± 11 94 ± 10 91 ± 5 
109 ± 10 80 ± 11 83 ± 4 
53± 15 57± 12 50± 9 
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brane may serve as a main target for the action of anthralin . 
Martinmaa et a l (14) showed that anthralin is oxidized via a 
free radical chain mechanism by which highly active anthralin-
peroxy-radicals and reduction products of oxygen a re generated. 
As suggested by Mustakallio [35) the target for such free 
radicals in a closed microenvironment of cells is likely to be 
t he cell membrane with which the radica ls can av idly interact. 
Using a mouse tail epidermis assay Bedard et a l [36) recently 
observed specific inhibition of the conversion of [1- 14C)arachi -
donic acid to lipoxygenase products (12-HETE) by anthralin. 
At a conce n t ration range of2- 200 J.LM of anthralin no significant 
effect was seen upon prostaglandin synthesis [36). Since it was 
shown that lipoxygenase products (i.e., L TB4 ) can be generated 
by ligand-receptor interaction in neutrophils [37) impairment 
of membrane associated lipoxygenase could in part be respon-
sible for tht anthralin mediated effects observed in the present 
study. 
Our observation that anthralin inhibits cellular motility and 
superoxide anion generation, but not degranulation of lysoso-
mal enzymes raises the question whether membrane sites par-
t icipating in the latter process remain inaccessible for anthralin 
or are protected by their biochemical composition. So far, direct 
evidence for a tra nsmembranous route of anthralin is still 
lacking. 
Finally, after topical application of Vaseline, anthralin is 
present in the upper epidermis at quantities comparable to 
those which may effectively inhibit PMN functions [38). It is 
intriguing to speculate that the effects reported in the present 
study may explain some of the actions of anthralin in psoriatic 
epidermis . This idea gains support by t he findings that dan-
throne as well as dimeric anthralin, which are known to be 
c linically ineffective [39,40) show complete absence of the PMN 
inhibitory effects seen with anthralin in this study. 
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expert technical assistance and Mrs. I. Bottjer for typing the manu-
script. 
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